|
|
Maki Nakayama, Joshua N. Beilke, Jean M. Jasinski, Masakazu Kobayashi, Dongmei Miao, Marcella Li, Marilyne G. Coulombe, Edwin Liu, John F. Elliott, Ronald G. Gill, George S. Eisenbarth
J Clin Invest. 2007;
117(7):1835
doi:10.1172/JCI31368
Abstract |
Full text
| PDF

N
OD mice with knockout of both native insulin genes and a mutated proinsulin transgene, alanine at position B16 in preproinsulin (B16:A-dKO mice), do not develop diabetes. Transplantation of NOD islets, but not bone marrow, expressing native insulin sequences (tyrosine at position B16) into B16:A-dKO mice rapidly restored development of insulin autoantibodies (IAAs) and insulitis, despite the recipients’ pancreatic islets lacking native insulin sequences. Splenocytes from B16:A-dKO mice that received native insulin–positive islets induced diabetes when transferred into wild-type NOD/SCID or B16:A-dKO NOD/SCID mice. Splenocytes from mice immunized with native insulin B chain amino acids 9–23 (insulin B:9–23) peptide in CFA induced rapid diabetes upon transfer only in recipients expressing the native insulin B:9–23 sequence in their pancreata. Additionally, CD4+ T cells from B16:A-dKO mice immunized with native insulin B:9–23 peptide promoted IAAs in NOD/SCID mice. These results indicate that the provision of native insulin B:9–23 sequences is sufficient to prime anti-insulin autoimmunity and that subsequent transfer of diabetes following peptide immunization requires native insulin B:9–23 expression in islets. Our findings demonstrate dependence on B16 alanine versus tyrosine of insulin B:9–23 for both the initial priming and the effector phase of NOD anti-islet autoimmunity.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(18)
| Title and authors |
Publication |
Year |
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
Roberto Mallone, Vedran Brezar, Christian Boitard
|
Clinical and Developmental Immunology
|
2011 |
Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion
J. F. Mohan, S. J. Petzold, E. R. Unanue
|
Journal of Experimental Medicine
|
2011 |
Insulin as a key autoantigen in the development of type 1 diabetes
Maki Nakayama
|
Diabetes Metab. Res. Rev.
|
2011 |
Molecular Targeting of Islet Autoantigens
Brian Stadinski, John Kappler, George S. Eisenbarth
|
Immunity
|
2010 |
Autoimmune polyglandular syndromes
Aaron W. Michels, Peter A. Gottlieb
|
Nat Rev Endocrinol
|
2010 |
Cross-priming in health and disease
Christian Kurts, Bruce W. S. Robinson, Percy A. Knolle
|
Nat Rev Immunol
|
2010 |
Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.
G Fousteri, A Dave, A Bot, T Juntti, S Omid, M von Herrath
|
Diabetologia
|
2010 |
Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes.
James F Mohan, Matteo G Levisetti, Boris Calderon, Jeremy W Herzog, Shirley J Petzold, Emil R Unanue
|
Nat Immunol
|
2010 |
Gamma delta T cell receptors confer autonomous responsiveness to the insulin-peptide B:9-23.
Li Zhang, Niyun Jin, Maki Nakayama, Rebecca L O'Brien, George S Eisenbarth, Willi K Born
|
Journal of Autoimmunity
|
2010 |
The anti-insulin trimolecular complex in type 1 diabetes
Aaron W Michels, Maki Nakayama
|
Current Opinion in Endocrinology, Diabetes and Obesity
|
2010 |
|